Efficacy and Safety of Lomitapide in Hypercholesterolemia
ConclusionsLomitapide improved most lipid parameters but not HDL-C or ApoA-1 in patients with HoFH and in non-HoFH patients, and gastrointestinal disorders were the most common adverse event. The possible benefits of lomitapide should be further evaluated and viewed against its possible long-term side effects.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Databases & Libraries | Gastroenterology | Heart | Liver | Statin Therapy | Study | Urology & Nephrology